How does Eskata work?

The mechanism of action for Eskata for the treatment of seborrheic keratosis (SK) is not known.

In December 2017 the FDA approved Eskata (hydrogen peroxide) 40% (w/w) topical solution from Aclaris Therapeutics. Eskata is a concentrated hydrogen peroxide formulation used to treat raised seborrheic keratoses (SKs). SKs are common, but often unsightly, non-cancerous skin growths.

Eskata is applied to the keratoses during an in-office procedure by a health care provider using a pen-like applicator. In studies, patients received up to two treatments with Eskata and were more likely to have all SKs completely cleared after two treatments than patients who received placebo.

What the side effects of Eskata?

In clinical studies with Eskata, common adverse reactions include redness (99%), stinging (97%), edema (91%), scaling (90%), crusting (81%), and itching (58%). Severe skin reactions can occur, including breakdown of the outer layer of the skin (erosion), ulcers, blisters, and scarring. Reactions can be severe, including breakdown of the outer layer of the skin (erosion), ulcers, blisters and scarring. Do not retreat with Eskata until any reaction from a previous use is cleared.